Knowledge is Power for Saving on Prescription Drugs

Knowledge is Power for Saving on Prescription Drugs

Two weeks ago, we had the opportunity to help a member (we’ll call him Joe) with a tough choice on his hands.  It was a situation many of us can relate to – Joe was deciding whether or not to buy an expensive medication for his child that would force a choice about which other life essential his family would then have to choose to go without.

After visiting a dermatologist with his daughter, Joe walked out of the office with a prescription to treat his daughter’s rosacea (caused by acne), for Noritate Cream.  Noritate has an active ingredient in it called metronidazole, a drug that was first made commercially available 55 years ago, in 1960.  Brand name Noritate is produced by Valeant Pharmaceuticals.  The metronidazole concentration in the product is at a level of 1%.  And the price tag – over $1650 for a 60 gram tube, or about $27.50 a gram.

After two days of calling pharmacies to try and locate lower pricing, calling the insurance company to see if an override was available or another product could be used, and looking for coupons online, their search yielded no helpful results.

Luckily we were able to intervene, identify another product (generic metronidazole cream, 0.75%), work with the doctor to change the prescription and find the product for under $60, or about $1.33 per gram.  Essentially, we provided information (both clinical and pricing) that was otherwise not available for the patient and prescriber to use as they evaluated options. 

For me, this interaction had a couple of important takeaways.

First, the majority of drug manufacturers don’t participate in the type of above mentioned activity.   There are, unfortunately, a few like Valeant and Turing that are consistently bringing negative press to the industry as a whole as they look to maximize profits on “me too” drugs - a drug that is structurally very similar to (or in this case the same as) already known drugs, with only minor differences.

Second, while the pharmaceutical industry as a whole faces mounting pressure to produce new drugs with lower price tags, I believe that ultimately free market economics will prevail and the simple rules of supply and demand will win. And while politicians are talking tough about new regulations with the looming elections just under a year away, based on past performance, I’m not convinced new legislation even on universally supported issues, is possible.  

Information is power, and accessing it at the right time can mean all the difference.  This is true for consumers and medical providers alike who are often times left in the dark about options and associated costs as they evaluate care decisions.  As the healthcare landscape changes, the demand for more information throughout the continuum of care will continue to soar.

Kristen D. Willey

Voluntary Benefits and Supplemental Health Leader

9 年

It's cases like this one that makes coming to work a rewarding experience.

Health care consumerism in action -- got to love it...

回复

I love reading articles like these. I can save my patients up to 90% on meds in my practice. Do the same with imaging, labs, and path. Cost of care will be deflated in the next decade with practices like ours.

回复
Thomas Morrow M.D.

Medical Director at Equity Health

9 年

The problem is that for most, there is simply a $10 or $20 copay and the patient has no real skin in the game. It is because of this type of pricing that the PBMs and health plans must pay attention and restrict access to the over priced products through preferred formularies and prior auth. But physicians also have to become more of a steward of this money. I have a hard time with a physician who hands out a $1600 prescription for basically a rash... and one that can be (and has been) treated with something at a small fraction of the price of the drug form prescribed. There is no way that physicians can keep up with all prices, but via EHRs they certainly can try. Must also ask the question...did this MD prescribe it because he is personally incented to do so? High likelihood. Until physicians start to pay attention, we will continue to have this type of story.... and by the way, thank you for finding an alternative!

Edward Castillo

Army CBRN Officer | HAZMAT Technician

9 年

Interested in this field. Specially the interaction of patient, provider, and insurer.

回复

要查看或添加评论,请登录

Michael Rea的更多文章

  • Pain is the Only Real Incentive to Reduce Drug Prices

    Pain is the Only Real Incentive to Reduce Drug Prices

    On May 11, President Trump made a big deal out of his blueprint for reigning in drug prices. Though short on details…

    13 条评论
  • Fighting the Flu, and the Price of Treatment

    Fighting the Flu, and the Price of Treatment

    It has been the worst flu season since the 2009-2010 swine flu epidemic, which sickened 60 million Americans…

    2 条评论
  • Drug Price Hikes Ring in 2018

    Drug Price Hikes Ring in 2018

    Another year, another serious hike in drug prices. On January 1, 2018, a total of 1,305 prescription drugs increased in…

    46 条评论
  • If EpiPen? Suddenly Became Free It Still Wouldn’t Solve America’s Drug Price Crisis

    If EpiPen? Suddenly Became Free It Still Wouldn’t Solve America’s Drug Price Crisis

    Market elasticity in American pharmaceuticals is unlike any other industry anywhere in the world. If you buy a car…

    7 条评论
  • Drug Prices — We Are Not Helpless

    Drug Prices — We Are Not Helpless

    Over the past 10 months, the discussion about drug prices in the United States has never been so hotly debated. It has…

    43 条评论
  • THE Pharmacy Disruptor

    THE Pharmacy Disruptor

    The market on prescription drug pricing is volatile and literally is changing on a daily (if not more frequent) basis…

    3 条评论
  • Generic doesn't mean Cheap

    Generic doesn't mean Cheap

    There is a common misconception in the world of pharmacy that “generic” means “cheap.” While these two words have…

    14 条评论
  • As pharmacy chain giants unite who's left with the bill?

    As pharmacy chain giants unite who's left with the bill?

    With the Walgreens, Rite Aid deal being confirmed, the market chatter is heating up once again. What does it all mean?…

    8 条评论
  • Drug Cost Debate from the Middle Seat

    Drug Cost Debate from the Middle Seat

    Yesterday, I had the opportunity to speak at a conference hosted by AHIP (America’s Health Insurance Plans) in Chicago.…

    10 条评论
  • You pay how much for drugs?

    You pay how much for drugs?

    I’ve never seen Americans so outraged by the news of the Turing Pharmaceuticals CEO, Martin Shkreli, raising the price…

    9 条评论

社区洞察

其他会员也浏览了